What Monitoring Is Needed for Tysabri-Associated PML?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Education to Occupational Exposure: The Tysabri Context

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). Regular monitoring through specific tests and clinical follow-up is crucial for early detection and management. The legacy of medical vigilance in biologic therapies underscores the importance of structured observation to balance treatment benefits against potential adverse events. This page outlines the key monitoring strategies and what they mean for patient safety.

Understanding Tysabri and Its Link to Progressive Multifocal Leukoencephalopathy

Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn disease. Its prescribing information contains a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is a severe demyelinating disease that typically occurs only in patients who are immunocompromised (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The boxed warning identifies three risk factors for developing PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation and Diagnosis of PML

The clinical presentation of PML can be variable. A large retrospective cohort study of 456 Italian PML patients observed between 1987 and 2024 described the demographic, clinical, radiological, and laboratory characteristics of the disease (https://pubmed.ncbi.nlm.nih.gov/40922664/). PML typically presents with progressive neurological deficits, including cognitive impairment, motor weakness, and visual disturbances. Diagnosis is confirmed by brain imaging showing demyelinating lesions and detection of JCV DNA in cerebrospinal fluid. The disease often leads to severe disability or death, as noted in the Tysabri boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanism of Action and Risk Factors

The mechanistic pathway linking Tysabri to PML involves the drug's effect on immune surveillance. Tysabri binds to alpha-4 integrins on lymphocytes, preventing their migration across the blood-brain barrier. This reduces immune surveillance in the central nervous system, allowing latent JCV to reactivate and cause PML. The risk is highest in patients with anti-JCV antibodies, as these antibodies indicate prior exposure to the virus. Longer treatment duration, especially beyond two years, further increases risk by prolonging the period of reduced immune surveillance. Prior use of immunosuppressants compounds this risk by further weakening the immune system.

Adverse Event Reporting and Regulatory Warnings

FDA adverse event reports (FAERS) for Tysabri list fatigue, multiple sclerosis relapse, headache, gait disturbance, fall, memory impairment, asthenia, malaise, drug ineffective, urinary tract infection, pain, balance disorder, hypoesthesia, pain in extremity, muscular weakness, nasopharyngitis, nausea, dizziness, mobility decreased, stress, cognitive disorder, muscle spasms, depression, and arthralgia among the most frequently reported events (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not specifically quantify PML incidence, they illustrate the range of adverse effects associated with the drug. The adequacy of warnings regarding Tysabri and PML is a key risk consideration. The boxed warning clearly states that Tysabri increases PML risk and that the disease usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). It also mandates monitoring patients for any new sign or symptom suggestive of PML and withholding Tysabri immediately at the first such sign (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, questions may arise about whether patients and healthcare providers fully understand the magnitude of risk, especially given the latency between exposure and symptom onset.

Legal Considerations for Tysabri-Related PML Cases

Attorney-related considerations for affected patients include the timeline between Tysabri exposure and documented PML harm. PML can develop months to years after starting Tysabri, with risk increasing after two years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This latency can complicate legal claims, as patients may not immediately associate their symptoms with the drug. Patients who develop PML may face severe disability or death, leading to substantial medical costs, lost income, and diminished quality of life. Legal action may seek compensation for these harms, alleging inadequate warning or failure to monitor. The boxed warning and restricted distribution program demonstrate that the manufacturer and FDA recognized the risk, but individual cases may involve questions about whether the warning was effectively communicated or whether monitoring protocols were followed.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how is it linked to PML?

Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn disease. It carries a boxed warning for increased risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus that often leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

The three key risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How is PML diagnosed?

PML is diagnosed through brain imaging showing demyelinating lesions and detection of JCV DNA in cerebrospinal fluid. Clinical presentation includes progressive neurological deficits such as cognitive impairment, motor weakness, and visual disturbances (https://pubmed.ncbi.nlm.nih.gov/40922664/).

What legal options do patients have if they develop PML after Tysabri?

Patients who develop PML may pursue legal action for compensation, alleging inadequate warning or failure to monitor. The latency between exposure and harm (often over two years) is a critical factor. Legal recourse may cover medical costs, lost income, and diminished quality of life.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.